On September 8th, AACC joined with other stakeholders in supporting the Verified Innovative Testing in American Laboratories (VITAL) Act introduced by Sen. Rand Paul. If enacted, VITAL would codify the existing CLIA oversight model for regulating laboratory developed tests (LDTs). Senator Paul introduced VITAL as alternative approach to the Verifying Accurate, Leading-edge IVCT Development (VALID) Act, sponsored by Reps. Larry Bucshon and Dianne DeGette, which would extend FDA oversight to LDTs. The association will continue working to ensure patient access to LDTs.